Form 4 for RLAY Relay Therapeutics, Inc.
Accepted 2024-01-18 00:00:00 ET · period of report 2024-01-16 · accession 0001209191-24-001843 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-01-18 | 2024-01-16 | RLAY | Patel Sanjiv | Pres, CEO, Dir | A - Grant | $0.00 | +762.4K | 764.0K | +45,870% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-16 | A | A | 762,360 | $0.00 | 764,022 | D | — | — | (F1) Represents restricted stock units ("RSUs") granted to the reporting person pursuant to the Issuer's 2020 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting. (F2) Includes 762,360 shares underlying RSUs. |